Sigilon Therapeutics, Inc. Uncategorized Contracts & Agreements
12 Contracts & Agreements
- Form of Contingent Value Right Agreement, by and among Eli Lilly and Company and a rights agent selected by Eli Lilly and Company and reasonably acceptable to Sigilon... (Filed With SEC on June 29, 2023)
- Offer Letter, between Sigilon Therapeutics, Inc. and Josias Pontes, dated October 23, 2019 (Filed With SEC on March 14, 2023)
- Offer Letter, between Sigilon Therapeutics, Inc. and Sarah Yuan, dated January 12, 2022 (Filed With SEC on March 14, 2023)
- Letter Agreement, dated February 10, 2023, between the Company and May Orfali, M.D (Filed With SEC on March 14, 2023)
- Letter Agreement, dated August 4, 2021, between the Company and Deya Corzo, M.D (Filed With SEC on March 14, 2022)
- Offer Letter, between Sigilon Therapeutics, Inc. and Deya Corzo, M.D. dated September 26, 2018 (Filed With SEC on March 14, 2022)
- Offer Letter, between Sigilon Therapeutics, Inc. and Philip Ashton-Rickardt, dated May 25, 2021 (Filed With SEC on March 14, 2022)
- Offer Letter, between Sigilon Therapeutics, Inc. and May Orfali, M.D. dated October 27, 2021 (Filed With SEC on March 14, 2022)
- Description of Registered Securities (Filed With SEC on March 18, 2021)
- Offer Letter, between Sigilon, Inc. and Devyn Smith, dated March 25, 2017 (Filed With SEC on November 13, 2020)
- Offer Letter, between Sigilon Therapeutics, Inc. and Glenn Reicin, dated May 8, 2019 (Filed With SEC on November 13, 2020)
- Offer Letter, between Sigilon Therapeutics, Inc. and Rogerio Vivaldi Coelho, M.D., dated April 23, 2018 (Filed With SEC on November 13, 2020)
